Literature DB >> 9012862

Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation.

R M Hudziak1, E Barofsky, D F Barofsky, D L Weller, S B Huang, D D Weller.   

Abstract

Oligomers possessing the Morpholino phosphorodiamidate backbone were evaluated for resistance to a variety of enzymes and biologic fluids. A 25-mer was incubated with nucleases, proteases, esterases, and serum, and the reaction mixtures were directly analyzed by MALDI-TOF mass spectrometry. The 25-mer was completely resistant to 13 different hydrolases and serum and plasma. The excellent resistance of Morpholino phosphorodiamidates to enzymatic attack indicates their suitability for in vivo use.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9012862     DOI: 10.1089/oli.1.1996.6.267

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  56 in total

1.  Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Authors:  Jagjeet K Kang; Alberto Malerba; Linda Popplewell; Keith Foster; George Dickson
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 2.  Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

Authors:  Yuko Shimizu-Motohashi; Shouta Miyatake; Hirofumi Komaki; Shin'ichi Takeda; Yoshitsugu Aoki
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

3.  In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.

Authors:  Yi Wang; Xinrong Liu; Kayoko Nakamura; Ling Chen; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biother Radiopharm       Date:  2009-10       Impact factor: 3.099

4.  Radiolabeled oligonucleotides for antisense imaging.

Authors:  Arun K Iyer; Jiang He
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

5.  Detection of Aspergillus fumigatus pulmonary fungal infections in mice with (99m)Tc-labeled MORF oligomers targeting ribosomal RNA.

Authors:  Yuzhen Wang; Ling Chen; Xinrong Liu; Dengfeng Cheng; Guozheng Liu; Yuxia Liu; Shuping Dou; Donald J Hnatowich; Mary Rusckowski
Journal:  Nucl Med Biol       Date:  2012-11-09       Impact factor: 2.408

6.  Analysis of circulating non-coding RNAs in a non-invasive and cost-effective manner.

Authors:  Yu-Min Wang; Michael Patrick Trinh; Yongzan Zheng; Kaizhu Guo; Luis A Jimenez; Wenwan Zhong
Journal:  Trends Analyt Chem       Date:  2019-07-05       Impact factor: 12.296

Review 7.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

8.  Morpholino-mediated knockdown in primary chondrocytes implicates Hoxc8 in regulation of cell cycle progression.

Authors:  Suzan Kamel; Claudia Kruger; J Michael Salbaum; Claudia Kappen
Journal:  Bone       Date:  2008-11-21       Impact factor: 4.398

9.  Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice.

Authors:  Sachchida Nand Pandey; Yi-Chien Lee; Toshifumi Yokota; Yi-Wen Chen
Journal:  Mol Ther       Date:  2013-11-14       Impact factor: 11.454

10.  Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.

Authors:  Benjamin W Neuman; David A Stein; Andrew D Kroeker; Amy D Paulino; Hong M Moulton; Patrick L Iversen; Michael J Buchmeier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.